Open AccessOral immunization with recombinant L actococcus lactis delivering a multi‐epitope antigen CTB ‐ UE attenuates H elicobacter pylori infection in mice
Author(s) -
Li Xinyang,
Xing Yingying,
Guo Le,
Lv Xiaobo,
Song Hui,
Xi Tao
Publication year - 2014
Publication title -
pathogens and disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.983
H-Index - 105
ISSN - 2049-632X
DOI - 10.1111/2049-632x.12173
Subject(s) - lactococcus lactis , epitope , immunization , helicobacter pylori , recombinant dna , antigen , microbiology and biotechnology , virology , immunology , biology , medicine , bacteria , lactic acid , gene , genetics , biochemistry
Urease is an essential virulence factor and colonization factor for H elicobacter pylori ( H . pylori ) and is considered as an excellent vaccine candidate antigen. However, conventional technologies for preparing an injectable vaccine require purification of the antigenic protein and preparation of an adjuvant. L actococcus lactis NZ 9000 ( L. lactis ) could serve as an antigen‐delivering vehicle for the development of edible vaccine. In previous study, we constructed a multi‐epitope vaccine, designated CTB ‐ UE , which is composed of the mucosal adjuvant cholera toxin B subunit ( CTB ), three Th cell epitopes and two B‐cell epitopes from urease subunits. To develop a novel type of oral vaccine against H. pylori , genetically modified L. lactis strains were established to secrete this epitope vaccine extracellularly in this study. Oral prophylactic immunization with recombinant L. lactis significantly elicited humoral anti‐urease antibody responses ( P < 0.001) and reduced the gastric colonization of H. pylori from 7.14 ± 0.95 to 4.68 ± 0.98 log 10 CFU g −1 stomach. This L. lactis oral vaccine offers a promising vaccine candidate for the control of H. pylori infection.